| Schedule of Significant Expense Categories |
The
following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s
single reporting segment. A reconciliation to the consolidated net loss for the three and nine months ended September 30, 2026 and 2025
is included at the bottom of the table below.
Schedule of Significant Expense Categories
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three
Months Ended
September 30, | | |
Nine
Months Ended
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Total
revenues | |
$ | 2,290,072 | | |
$ | 114,574 | | |
$ | 2,599,568 | | |
$ | 831,287 | |
| Program
expenses (1) | |
| | | |
| | | |
| | | |
| | |
| Lead
clinical candidate | (1) |
| 1,089,005 | | |
| 1,440,851 | | |
| 3,887,033 | | |
| 2,490,471 | |
| Other
research and development programs | (1) |
| 18,777 | | |
| 555,215 | | |
| 32,671 | | |
| 731,602 | |
| Non-program
expenses (2) | |
| 954,306 | | |
| 792,412 | | |
| 2,815,783 | | |
| 2,528,542 | |
| Personnel
costs | |
| 1,022,415 | | |
| 633,880 | | |
| 3,226,679 | | |
| 2,746,787 | |
| Stock-based
compensation | |
| 74,094 | | |
| 53,256 | | |
| 197,637 | | |
| 189,463 | |
| Total
segment operating income (loss) | |
| (868,525 | ) | |
| (3,361,040 | ) | |
| (7,560,235 | ) | |
| (7,855,578 | ) |
| Other
income (loss) (3) | |
| 202,333 | | |
| 174,208 | | |
| 599,554 | | |
| 598,157 | |
| Net
income (loss) | |
$ | (666,192 | ) | |
$ | (3,186,832 | ) | |
$ | (6,960,681 | ) | |
$ | (7,257,421 | ) |
| |
(1) |
Includes
external research and development expenses. |
| |
(2) |
Includes
general and administrative expenses, information technology, infrastructure, facilities, intellectual property, and legal and professional
fees. |
| |
(3) |
Includes
interest income and income tax expense. |
|